Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease

NCT ID: NCT06539624

Last Updated: 2024-10-30

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-10-16
• Study Completion Date: 2027-04-09

Brief Summary

Objective: To explore the safety and tolerability of different doses of EXG110 with Fabre disease

Detailed Description

An open-label, multicenter, single-arm, non-randomized, dose-escalation, and recommended dose-extension clinical design was used to evaluate the safety and efficacy of a single intravenous administration of different doses of EXG110 in patients

Conditions

Fabry Disease

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dose escalation-Cohort 1

Genetic : EXG110

Group Type: EXPERIMENTAL

EXG110 injection

Intervention Type: GENETIC

EXG110 is a recombinant adeno-associated virus (rAAV) that not only significantly increases plasma AGA activity, but is also highly expressed in target organs such as the heart and kidneys.EXG110 will be administered in a single dose by intravenous infusion.

Dose escalation-Cohort 2

Genetic : EXG110

Group Type: EXPERIMENTAL

EXG110 injection

Intervention Type: GENETIC

EXG110 is a recombinant adeno-associated virus (rAAV) that not only significantly increases plasma AGA activity, but is also highly expressed in target organs such as the heart and kidneys.EXG110 will be administered in a single dose by intravenous infusion.

Dose escalation-Cohort 3

Genetic : EXG110

Group Type: EXPERIMENTAL

EXG110 injection

Intervention Type: GENETIC

EXG110 is a recombinant adeno-associated virus (rAAV) that not only significantly increases plasma AGA activity, but is also highly expressed in target organs such as the heart and kidneys.EXG110 will be administered in a single dose by intravenous infusion.

Dose escalation-Cohort 4

Genetic : EXG110

Group Type: EXPERIMENTAL

EXG110 injection

Intervention Type: GENETIC

EXG110 is a recombinant adeno-associated virus (rAAV) that not only significantly increases plasma AGA activity, but is also highly expressed in target organs such as the heart and kidneys.EXG110 will be administered in a single dose by intravenous infusion.

Interventions

EXG110 injection

EXG110 is a recombinant adeno-associated virus (rAAV) that not only significantly increases plasma AGA activity, but is also highly expressed in target organs such as the heart and kidneys.EXG110 will be administered in a single dose by intravenous infusion.

Intervention Type: GENETIC

Eligibility Criteria

Inclusion Criteria

1. At the time of signing the informed consent, age ≥7, male or female

2. Clinical symptoms (at least one Fabry disease related symptom) and genetic diagnosis of Fabry disease,

3. Prior or no prior ERT treatment

4. Have renal or cardiac involvement (adults only)

5. All subjects of reproductive age voluntarily took effective contraception and prohibited sperm donation from entering the screening period until 52 weeks after dosing (main study period)

6. The subjects voluntarily participate and are fully informed, fully understand the research, can comply with the requirements of the research protocol, and are willing to complete the research as planned, and voluntarily provide biological samples for testing according to the requirements of the protocol

Exclusion Criteria

1. Screening period laboratory test results: a) aspartate aminotransferase or alanine aminotransferase > 1.5× upper limit of normal (ULN);b) Total bilirubin > 1.5× upper limit of normal (ULN);c) Alkaline phosphatase > 2× upper limit of normal (ULN);d) Albumin < lower limit of normal (LLN)

2. There was a clinically significant increase in AFP during the screening period

3. Serum virology test: a) Hepatitis B: Hepatitis B virus surface antigen (HBsAg) positive, and hepatitis B virus-deoxyribonucleic acid (HBV-DNA) higher than the upper limit of normal detection;b) Hepatitis C: if the hepatitis C virus (HCV) antibody is positive, and the hepatitis C virus-ribonucleic acid (HCV-RNA) is higher than the upper limit of normal test value;c) Syphilis: positive for syphilis screening (Tp-Ab) and positive for syphile-specific antibodies;d) HIV: Known human immunodeficiency virus (HIV) positive history or HIV screening positive

4. AVT917 (>1:50), anti-AGA antibody positive(>1:2560)

5. C3 lower than the normal range, C5b-9 higher than the normal range, anti-AVT917 IgM positive

6. Current or have a history of serious cardiovascular disease and surgical history

7. Current underlying liver disease or history of liver disease, as assessed by the investigator, that may affect the safety assessment of the drug

8. Renal disease in adult and the slope of kidney >5 mL/min/1.73m²/year

9. Subjects with poorly controlled diabetes after drug treatment (e.g., HbA1c≥8%);

10. Acute/chronic infection or other chronic disease that the investigator determines will increase the risk of participants participating in the study

11. Patients with a history of malignant tumor or currently suffering from any malignant tumor (except for the following tumor diseases: skin basal cell carcinoma, cervical carcinoma in situ, breast carcinoma in situ, skin squamous cell carcinoma has been controlled after treatment);

12. Have malignancy cancer

13. Patients with active autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, immune vasculitis, inflammatory bowel disease, etc.);

14. known history of allergy to the components of the investigational products

15. Patients with a history of drug use or drug abuse or alcoholism

16. Use of systemic (intravenous or oral) immunomodulators within the past 6 months or currently

17. Initiation of treatment with blood pressure lowering drugs that affect proteinuria levels (such as angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or angiotensin-receptor/enkephalin inhibitors) within 4 weeks prior to screening, or changes in the therapeutic dose of these drugs within 4 weeks prior to screening;

18. Has received, or is currently receiving, a clinical trial of another investigational drug/medical device or treatment (other than vitamins and minerals) within 3 months prior to signing the informed consent (or within 5 half-lives of the investigational drug, whichever is longer)

19. Previous treatment with gene therapy products

20. Those who had received live attenuated vaccine/vaccine within 12 weeks prior to screening or planned to receive it during the study

21. Other clinical conditions that the investigators felt needed to be ruled out

• Minimum Eligible Age: 7 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The Children's Hospital of Zhejiang University School of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Mao Jianhua

Vice President of the hospital

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jianhua Mao, PhD

Role: PRINCIPAL_INVESTIGATOR

Children's Hospital, Zhejiang University School of Medicine

Locations

Shanghai Children's Medical Center

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Children's Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Site Status: RECRUITING

Countries

China

Central Contacts

Jianhua Mao, PhD

Role: CONTACT

maojh88@zju.edu.cn

13516819071

Facility Contacts

Lei Yin, PhD

Role: primary

yinlei@scmc.com.cn

13641673203

Mao Jianhua, MD

Role: primary

maojh88@zju.edu.cn

13616819071

Other Identifiers

EXG110-011

Identifier Type: -

Identifier Source: org_study_id